This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Two compounds that target the endocannabinoid system are currently in development to treat scleroderma – and they’re already in clinicaltrials. Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2.
Both parties to this new relationship are committed to excellence in clinicalresearch and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
The study is expected to be the world’s first Phase 2a clinicaltrial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinicaltrial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
Desai brings to Ehave the ability to visualize opportunities and execute creative strategic solutions, while developing deep networks and relationships within the industry. Research in the area of mental health has been Dr. Nitin Desai’s passion. Ben Kaplan, CEO of Ehave, Inc. ” About Ehave, Inc. Ehave, Inc. Email: ir@ehave.com.
There is an urgent need for objective, scientifically sound and robust clinicaltrials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. In Canada, mental health issues affect more than 6.7
“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of ClinicalDevelopment & Regulatory Affairs. Visit [link].
Currently, the sole federally licensed producer of cannabis for clinicalresearch is the University of Mississippi. ” The agency said that the policy change was necessary because the existing system provided “no clear legal pathway for commercial enterprises to produce marijuana for product development.”
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. About RYAH Group, Inc.
As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.
The recently proposed bipartisan bill pledges $75 million towards research into the therapeutic potential of psychedelic substances in treating post-traumatic stress disorder (PTSD). The Grant Program Details The heart of this landmark legislation lies in the development of a robust grant program. In a bold and unprecedented move, U.S.
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
Virtual ClinicalTrials transcend geographic, mobility and economic barriers. Clinicaltrials are medical research projects involving human participants. However, the costs of conducting a full-scale clinicaltrial can be prohibitive, posing barriers to research for cannabis companies.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. Lead researcher Sue Sinsley of SRI says: “While most states in the U.S. A Vicious Circle. .
The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. Research is Limited Due to Many Obstacles.
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable ClinicalTrials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinicaltrials in the areas of psychedelics and nutraceuticals, among other substances of study.
We’re thrilled to be pursuing SalA and progressing research, as we strive for new treatments.”. Importantly, Revixia’s product will be paired with a digital therapeutic being developed by atai company Introspect Digital Therapeutics, with the aim of streamlining preparation, integration, and continued patient engagement. “In
GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS” after opening for trading on Friday, July 2 at $22. The financing was co-led by RA Capital and RTW Investments, LP, U.S.
The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. . – July 28, 2021) – PharmaDrug Inc.
Research Team to Study the Impact of CBD on Spinal Injury Pain. Professor Luke Henderson is set to be the study’s lead investigator and he explains that the unfortunate truth for more than half of spinal cord injury patients is the development of chronic pain. Dr. Carins is a postdoctoral researcher who completed her Ph.D.
The Financing will allow the Company to continue progressing its R&D, clinicaltrials and technology initiatives. “I I firmly believe the current downtrend in the industry is an overreaction to incredibly positive results from Compass Pathways 2b trial, which have clearly been misinterpreted. DENVER, Dec.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
This collaboration is intended to include research into COMP360 psilocybin therapy and other novel therapies that may be developed by COMPASS in areas of unmet need such as depression, post-traumatic stress disorder (PTSD) and anorexia. This is a really exciting prospect and has the potential to change people’s lives for the better.”.
Silo Pharma’s notice of allowance paves the way toward clinicaltrials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Looking to the Future.
MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. European Regulatory Lead Executive Summary.
The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinicalresearch organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.
(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.
If this mechanism is forced to be used repeatedly and often, the body does not properly heal or develop. Often, Post-Traumatic Stress Disorder, a debilitating and chronic illness, can develop. About 10 of every 100 women (or 10%) develop PTSD sometime in their lives compared with about 4 of every 100 men (or 4%).
.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinicaltrial to further understand the effects of CBD in epilepsy treatment.
NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.
A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. ClinicalTrial Sample Size.
What this means for CBN research These results are, in a word, impressive. Sleep is not often the focus of clinicaltrials on cannabis; rather it is often a secondary outcome. A 2021 review examined all 99 of the existing human research studies on CBN and found just eight studies that met stringent criteria for reliable results.
Extensive research in the United States and England on cannabis in the 1930s came to a halt with the beginning of World War II and did not pick up again afterwards due to the various laws and regulations that classified the plant as a drug.Legal issuescontinued to inhibit serious study until half a century ago, when Prof.
At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. “At At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer.
Shanti”), and all its assets focused on psychedelic MDMA-based drug development. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinicaltrials for the purposes of novel drug development. billion in 2030.
Filament Health partnered with TrPR Psychedelic Research Program at UCSF to advance drug candidates through clinicaltrials. a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. Industry Developments. (CSE: NOVA).
Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment, however regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance.
They describe their goal as “marrying cutting edge cannabis cultivation with biopharmaceutical research and development.” Their state-of-the-art, 28,000 square-foot cultivation lab and custom “tissue propagation” techniques provide raw materials for ongoing research studies. Find Parkinson’s Disease Relief.
Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. The new Congress was just sworn in yesterday, and they are not wasting any time.
PsyBio intends to continue utilizing its resources to rapidly develop and test new drug candidates within this and other psychedelic categories in anticipation of launching future clinicaltrials. OXFORD, Ohio and COCONUT CREEK, Fla., 16, 2021 /CNW/ — PsyBio Therapeutics Corp. ” About PsyBio Therapeutics Corp.
This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Furthermore, pharmaceutical companies often fund and initiate randomised clinicaltrials to validate their drugs.
Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. A fascinating new clinicaltrial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Magic Mushrooms: The Ticket to a Stress-Free MRI?
capital markets, negative global economic conditions, potential negative developments in our clinicaltrials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. About Bionomics Limited. The post Bionomics Announces Plans to Conduct U.S.
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinicaltrial.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content